An interventional study of Flexible ePROM-guided Scheduling System and electronic patient reported outcome measures (ePROMs) in Chronic Dermatological Conditions, Eczema and Urticaria, sponsored by National University Hospital, Singapore. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Health services research
The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:
503 studies on the registry are indexed under Eczema; 89 are open to participants now.
This study's planned enrollment of 250 is above the median of 91 across 401 interventional studies indexed under Eczema.
Browse Eczema studies →National University Hospital, Singapore is the lead sponsor of 454 studies on the registry; 99 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention arm will not receive routine follow-up appointments at the end of their consultation. Instead, their monthly ePROM responses will feed a two-layer Bayesian decision system to determine appointment need.
Behavioral: Flexible ePROM-guided Scheduling System · Behavioral: electronic patient reported outcome measures (ePROMs)
Participants in the control arm will continue standard care, with follow-up appointments scheduled at the end of each consultation. The ePROM responses may be used by patients for self-tracking and will be available to clinicians to inform decision-making at subsequent visits.
Behavioral: electronic patient reported outcome measures (ePROMs)
Monthly ePROM responses will feed a Bayesian decision system to determine appointment need, which will then be used to make recommendations to patients for scheduling of appointments.
Monthly electronic patient reported outcome measures (ePROMs) surveys will be sent to patients' mobile devices to capture self-reported disease severity data.
Number of actualised outpatient visits
Difference in actualised outpatient visits (in-person + teleconsult) over 12 months (effectiveness outcome).
Time frame: baseline to week 52
Proportion of completed monthly ePROMs
Difference in proportion of completed monthly ePROMs (implementation outcome)
Time frame: baseline to week 52
No-show rate
Number of appointments missed without prior rescheduling or cancellation
Time frame: baseline to week 52
Cancelled or rescheduled appointments
Appointments booked but cancelled or rescheduled before the actual appointment date
Time frame: baseline to week 52
Urgent care or unscheduled visits
Emergency department visits or other urgent care visits related to patient's dermatological condition
Time frame: baseline to week 52
Skin-specific Quality of Life Impairment
Changes in quality of life using the Dermatology Life Quality Index (DLQI). Minimum Score: 0 (no impact on quality of life). Maximum Score: 30 (extremely large impact on quality of life).
Time frame: baseline, 6 months, 12 months
Clinician-assessed disease severity
Clinician-assessed disease severity using body surface area and the investigator global assessment on a 0-5 NRS
Time frame: baseline to week 52
Acceptability of the intervention
Assessed using the Theoretical Framework of Acceptability
Time frame: week 52
Perceived burden of engaging with the intervention
Research questionnaire assessing perceived burden of intervention use
Time frame: baseline, 6 months, 12 months
Fidelity to the scheduling algorithm
The extent to which algorithm-generated recommendations were followed, overridden, or superseded
Time frame: baseline to week 52
Barriers and facilitators to implementation
Explored through semi-structured qualitative interviews
Time frame: week 52
Bayesian Decision-layer outputs
Decision-layer outputs, including monthly posterior summaries and posterior predictive probabilities for each appointment category
Time frame: baseline to week 52
No study locations are listed for this record.
Plan to share: Yes — IPD shared includes de-identified demographics, disease outcomes and measures.
Supporting information: Study protocol, Informed consent form, Analytic code
Time frame: IPD and supporting information will be available from the time of publication and for four years thereafter.
Access criteria: IPD and supporting information will be available from the study team on a case-by-case basis upon request.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jun 2029, 33 months later.
Of 45 non-industry interventional studies with no phase under Eczema, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 33 months is above that.
Counting every sponsor, half of 78 studies reached it within 11 months; a quarter within 4 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Hospital, Singapore →